Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 9/20 | 0.32 |
| ▸ | CA2 | P00918 | 9/20 | 0.32 |
| ▸ | CA9 | Q16790 | 8/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298989 | 1.00 | EPHX1 (0.33) | EPHX1CA1CA2CA9LPAR3 | |
| SCHEMBL7859946 | 0.76 | DNM1 (0.35) | EPHX1CA1CA2CA9CA12 | |
| SCHEMBL8533488 | 0.76 | — | — | |
| SCHEMBL8533485 | 0.76 | — | — | |
| SCHEMBL7771454 | 0.74 | CYP3A4 (0.30) | — | |
| SCHEMBL9717359 | 0.74 | DNM1 (0.39) | EPHX1CA1CA2CA9LPAR3 | |
| SCHEMBL12496491 | 0.71 | — | — | |
| SCHEMBL9726224 | 0.70 | ALDH1A1 (0.42) | EPHX1TSHR | |
| SCHEMBL9726226 | 0.70 | ALDH1A1 (0.42) | EPHX1TSHR | |
| SCHEMBL2880462 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | claimed |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | claimed |
| EP-3397625-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | Agios Pharmaceuticals, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| WO-2017117372-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | WO | claimed |
| EP-3139914-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Panoptes Pharma GmbH (AT) | 2017-03-15 | — | — | EP | claimed |
| WO-2015169944-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PANOPTES PHARMA GES.M.B.H. (AT) | 2015-11-12 | — | — | WO | claimed |
| EP-2427186-A2 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2012-03-14 | — | — | EP | claimed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | claimed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | claimed |
| WO-2010128050-A2 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-11 | — | — | WO | claimed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | claimed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | claimed |
| EP-4362968-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010128050-A2 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | EPHX1 545/4885CA1 607/4885CA2 680/4885 |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | EPHX1 859/4885CA1 631/4885CA2 950/4885 |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | EPHX1 320/4885CA1 1413/4885CA2 2313/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | EPHX1 32/4885CA1 3874/4885CA2 1046/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | EPHX1 320/4885CA1 1413/4885CA2 2313/4885 |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | EPHX1 32/4885CA1 3874/4885CA2 1046/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | EPHX1 768/4885CA1 3458/4885CA2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.